Erudio Healtherudio.com
Drug
Patritumab deruxtecan trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying patritumab deruxtecan: HERTHENA-Breast04. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 3 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| HERTHENA-Breast04 NCT07060807 · Merck Sharp & Dohme LLC | hormone receptor-positive, HER2-negative unresectable locally advanced or metastatic breast cancer | Phase 3 | 27 | 5 | Focused | Nov 19, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| HERTHENA-Lung02 NCT05338970 · Daiichi Sankyo DeepView → | advanced EGFR-mutated nonsquamous NSCLC after third-generation EGFR TKI | Phase 3 | Deep | View | |||
| HERTHENA-Lung01 NCT04619004 · Daiichi Sankyo DeepView → | previously treated locally advanced or metastatic EGFR-mutated NSCLC | Phase 2 | Deep | View | |||
| TUXEDO-3 NCT05865990 · MedSIR DeepView → | breast cancer/NSCLC brain metastases; solid tumor leptomeningeal disease | Phase 2 | Deep | View | |||